Developer docs
API playgroundTry for free, no card

Search company profiles

Intelligent Bio Solutions

Full company profile

uuid0000bb8

Namestring
Intelligent Bio Solutions
Legal namestring
Intelligent Bio Solutions Inc.
Websiteurl
ibs.inc
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company that develops and commercializes non-invasive drug screening products based on fingerprint sweat analysis. Founded in 2017 and headquartered in New York with operating offices in Sydney (Australia) and Cambridge (UK), INBS serves workplace safety programs in construction, transportation/logistics, manufacturing, mining, and forensic/coroner settings, plus justice and rehabilitation programs through its continuous-monitoring product line. The company sells into 35+ countries and territories via direct enterprise sales and a network of more than a dozen regional distributors, reporting 480+ active customer accounts.

The company's core offering is the Intelligent Fingerprinting Drug Screening System, which pairs single-use tamper-proof Drug Screening Cartridges (lateral flow assay with fluorescence-labelled antibodies) with the portable DSR-Plus fluorescence reader. Sample collection takes seconds and results are displayed in under ten minutes at the point of collection, with cartridge revenue at 66% of Q3 FY2026 revenue ($703,538, up 59% YoY). The portfolio also includes the SmarTest Patch, a wearable 7–10-day continuous sweat-monitoring patch targeting justice and rehabilitation use cases, and a confirmatory LC-MS/MS laboratory testing kit executed through NATA-accredited partner Racing Analytical Services Limited. INBS holds eight granted European patents covering the underlying sweat-analysis methodology and reader/cartridge technology.

INBS operates a razor-razorblade model: DSR-Plus reader placements (up 104% YoY in Q2 FY2026 to $246,519) build the installed base that generates recurring cartridge consumable revenue and other consumables/services (21% of Q3 revenue). Pricing is quote-based and not publicly disclosed, though management cites approximately 50% cost reduction vs. urine-based testing as the headline value proposition. Q3 FY2026 revenue was $1.06M (up 46% YoY), nine-month FY2026 revenue was $3.07M (up 39% YoY), and gross margin crossed 50% for the first time. The company is actively pursuing FDA 510(k) clearance — Cut-off Study completed April 2026, Interference and Method Comparison studies initiated June 2026 — which would unlock the multi-billion-dollar U.S. drug screening market and the projected ~$1.62B U.S. roadside testing market by 2030. To support scaling, INBS signed a strategic manufacturing partnership with Syrma Johari MedTech (announced December 2025) projected to deliver over 40% production cost savings and approximately 20 percentage points of gross margin improvement at ~4x prior capacity, with the first reader shipments received in February 2026.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBotany, Australia
HQ citystring
Botany
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug screening systems, fingerprint drug testing, non-invasive diagnostic devices, workplace drug screening, point of care testing
Industry1 code
PRIMARYHLAHAOAG
Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Drug Screening Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Cartridge Sales (Recurring Consumables)
TypeUsage Based
Description

Razor-razorblade model where reader placements generate recurring cartridge revenue. Cartridge sales represent 66% of quarterly revenue ($703,538 in Q3 FY2026), up 59% year-over-year. This is the primary growth driver as installed base expands.

stocktitan.net
2Reader Hardware Sales
TypeHardware Sales
Description

Initial reader hardware sales (DSR-Plus fluorescence reader) that create the installed base for recurring cartridge revenue. Reader sales surged 104% year-over-year in Q2 FY2026 to $246,519.

stocktitan.net
3Other Revenue
TypeProfessional Services
Description

Other sales including supplementary products and services, representing 21% of Q3 revenue ($217,857), up 80% year-over-year, indicating broadening product ecosystem.

stocktitan.net
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Intelligent Fingerprinting Drug Testing Solution
Description

Non-invasive fingerprint sweat analysis drug testing system that screens for recent drug use including opiates, cocaine, methamphetamine, and cannabis with results in under ten minutes

ibs.inc
+1 more record
Core offering1 text field

Intelligent Bio Solutions develops and sells the Intelligent Fingerprinting Drug Screening System, which uses lateral flow assay cartridges and a portable DSR-Plus fluorescence reader to detect drug metabolites in fingerprint sweat. Sample collection takes seconds and results are produced in under ten minutes at the point of collection. The company also sells the SmarTest Patch, a wearable sweat patch for continuous drug detection over 7–10 days.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 50% cost reduction vs urine-based testing
+5 more records
Product overview1 text field

Intelligent Bio Solutions offers a unified portfolio of non-invasive drug testing products based on fingerprint sweat analysis. The core offering is the Intelligent Fingerprinting Drug Screening System, comprising single-use Drug Screening Cartridges and the portable DSR-Plus Drug Screening Reader, which provides rapid point-of-collection screening for opiates, cocaine, methamphetamine, and cannabis with results in under 10 minutes. This is complemented by the SmarTest Patch, a wearable sweat patch enabling continuous 7-10 day drug monitoring for longer-term detection in justice and rehabilitation settings. The portfolio also includes a Confirmatory Drug Test Kit with LC-MS/MS laboratory analysis through accredited partner RASL for situations requiring definitive confirmation of non-negative screening results. Together, these products provide both immediate and continuous non-invasive sweat-based drug detection solutions.

Product and service4 records
1Intelligent Fingerprinting Drug Screening System
CategoryDrug Screening System
Description

A rapid, non-invasive drug screening system that detects recent drug use (opiates, cocaine, methamphetamine, cannabis) by analysing fingerprint sweat. Combines single-use Drug Screening Cartridges with the portable DSR-Plus Reader; samples collected in seconds and results returned in under ten minutes. Designed for workplace screening by non-specialist staff.

2Drug Screening Cartridges
CategoryConsumables
Description

Single-use, tamper-proof lateral flow assay cartridges that collect fingerprint sweat and use fluorescence-labelled antibodies to selectively detect specific drugs or their metabolites. Self-locking sample seals support chain-of-custody integrity. Sold as recurring consumables for use with the DSR-Plus Reader.

3DSR-Plus Drug Screening Reader
CategoryHardware Device
Description

A portable, highly sensitive fluorescence measurement instrument used to read Drug Screening Cartridges, producing negative or non-negative results for each drug within minutes. Designed for use by non-laboratory workplace personnel without specialised facilities.

4SmarTest Patch
CategoryWearable Diagnostic Device
Description

A discreet, wearable sweat drug testing patch worn on the upper arm, chest, or back that enables continuous drug detection over a 7 to 10-day period. Tamper-evident and water-resistant; monitors substances including fentanyl, cocaine, opiates, benzodiazepine, buprenorphine, and methadone. Designed for longer-term monitoring in justice and rehabilitation settings.

Scale indicator15 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-24
Description

Initial 13-site deployment with UK subsidiary of Bouygues Construction (global construction firm with 35,600 employees across 50+ countries). Transition from third-party testing services to in-house INBS fingerprint drug testing. Joint ROI analysis validated superior hygiene, operational efficiency, and cost savings. Viewed as collaborative partnership rather than traditional supplier agreement.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-01
Description

Nationwide clinical research site network partnership for FDA 510(k) clinical studies. Conducting Interference Study enrolling 75 participants, Method Comparison Study with 135 donor and 9 operator participants, and supporting Cut-off Study. Studies conducted under ICH GCP Guidelines to generate clinical evidence required for FDA submission.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-12-31
Description

Strategic manufacturing partnership to produce Intelligent Fingerprinting Drug Screening Reader. Expected to deliver over 40% reduction in annual production costs and approximately 20 percentage point improvement in gross margin. Syrma Johari's manufacturing capacity is approximately four times INBS's current capability with ISO 13485, MDSAP, FDA, and GMP certifications across 14 manufacturing locations in India, Europe, and the US. First readers successfully manufactured and shipped in February 2026.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-18
Description

Non-exclusive strategic alliance to jointly develop and commercialize non-invasive testing and wearable health monitoring technologies. Leverages Vlepis's wearable patch and sensor technologies alongside INBS's fingerprint-based testing and SmarTest Patch products. Targets consumer health monitoring market valued at USD 42.7 billion in 2024, projected to reach USD 168.3 billion by 2030. Companies will combine R&D capabilities, distribution networks across 24+ countries, and regulatory expertise.

Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

NATA-accredited laboratory partner performing fingerprint confirmatory drug testing procedure. Provides gold standard LC-MS/MS analysis to confirm screening results and validate system accuracy for FDA 510(k) submission studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

OraSure develops rapid point-of-care diagnostics including oral-fluid drug testing products (Intercept). It is the most direct comparable to INBS in non-invasive rapid drug screening.

TypeDirect peer
Description

Psychemedics pioneered hair-based workplace drug testing. It competes in the same employer drug-testing use cases as INBS via a different non-invasive sample matrix.

TypeBroad incumbent
Description

Quest Diagnostics operates one of the largest clinical laboratory networks in the U.S. and is a major employer drug testing incumbent. INBS positions itself as a faster, point-of-collection alternative to lab-based urine testing.

4Abbott Laboratories (Diagnostics)
TypeBroad incumbent
Description

Abbott's diagnostics franchise spans rapid point-of-care and laboratory drug/toxicology testing. As a broad incumbent, Abbott is a likely competitor or potential partner for any FDA-cleared rapid drug screening platform.

TypeBroad incumbent
Description

Thermo Fisher offers laboratory analytical instruments, reagents, and clinical diagnostics consumables overlapping with both INBS's DSR-Plus reader and lateral flow cartridge chemistry.

6Drägerwerk
TypeDirect peer
Description

Dräger's Dräger DrugTest 5000 is a well-established oral-fluid point-of-collection workplace drug testing system, making it a direct head-to-head competitor in safety-critical industries where INBS also sells.

TypeEmerging player
Description

Confirm BioSciences sells rapid urine- and saliva-based drug testing kits to workplace, clinical, and at-home users — an emerging player in the same customer segments INBS targets via fingerprint sweat.

TypeEmerging player
Description

Premier Biotech manufactures and distributes point-of-care drug screening devices and test cups for workplace and clinical use, overlapping with INBS's workplace drug-testing go-to-market.

TypeDirect peer
Description

American Screening distributes rapid drug test kits and point-of-care testing devices for workplace, clinical, and at-home use across multiple methodologies including urine, saliva, and surface tests.

TypeBroad incumbent
Description

Bio-Rad manufactures clinical diagnostics and life science research instruments, including quality controls and immunoassay reagents relevant to lateral flow and laboratory drug screening workflows.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment7 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intelligent Bio Solutions

Drug Screening Diagnosticsibs.inc

What Intelligent Bio Solutions does

Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company that develops and commercializes non-invasive drug screening products based on fingerprint sweat analysis. Founded in 2017 and headquartered in New York with operating offices in Sydney (Australia) and Cambridge (UK), INBS serves workplace safety programs in construction, transportation/logistics, manufacturing, mining, and forensic/coroner settings, plus justice and rehabilitation programs through its continuous-monitoring product line. The company sells into 35+ countries and territories via direct enterprise sales and a network of more than a dozen regional distributors, reporting 480+ active customer accounts.

The company's core offering is the Intelligent Fingerprinting Drug Screening System, which pairs single-use tamper-proof Drug Screening Cartridges (lateral flow assay with fluorescence-labelled antibodies) with the portable DSR-Plus fluorescence reader. Sample collection takes seconds and results are displayed in under ten minutes at the point of collection, with cartridge revenue at 66% of Q3 FY2026 revenue ($703,538, up 59% YoY). The portfolio also includes the SmarTest Patch, a wearable 7–10-day continuous sweat-monitoring patch targeting justice and rehabilitation use cases, and a confirmatory LC-MS/MS laboratory testing kit executed through NATA-accredited partner Racing Analytical Services Limited. INBS holds eight granted European patents covering the underlying sweat-analysis methodology and reader/cartridge technology.

INBS operates a razor-razorblade model: DSR-Plus reader placements (up 104% YoY in Q2 FY2026 to $246,519) build the installed base that generates recurring cartridge consumable revenue and other consumables/services (21% of Q3 revenue). Pricing is quote-based and not publicly disclosed, though management cites approximately 50% cost reduction vs. urine-based testing as the headline value proposition. Q3 FY2026 revenue was $1.06M (up 46% YoY), nine-month FY2026 revenue was $3.07M (up 39% YoY), and gross margin crossed 50% for the first time. The company is actively pursuing FDA 510(k) clearance — Cut-off Study completed April 2026, Interference and Method Comparison studies initiated June 2026 — which would unlock the multi-billion-dollar U.S. drug screening market and the projected ~$1.62B U.S. roadside testing market by 2030. To support scaling, INBS signed a strategic manufacturing partnership with Syrma Johari MedTech (announced December 2025) projected to deliver over 40% production cost savings and approximately 20 percentage points of gross margin improvement at ~4x prior capacity, with the first reader shipments received in February 2026.

Intelligent Bio Solutions firmographics

Firmographics
Name
Intelligent Bio Solutions
Legal name
Intelligent Bio Solutions Inc.
Website
https://ibs.inc
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Intelligent Bio Solutions industry classification

Industry
Product category
Drug Screening Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAHAOAG
Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Drug screening systems
  • Fingerprint drug testing
  • Non-invasive diagnostic devices
  • Workplace drug screening
  • Point of care testing

Where Intelligent Bio Solutions is headquartered

Location

Headquarters

HQ city
Botany
HQ country
Australia
HQ region
Oceania

Offices3 records

Markets served

Intelligent Bio Solutions business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Cartridge Sales (Recurring Consumables): Razor-razorblade model where reader placements generate recurring cartridge revenue. Cartridge sales represent 66% of quarterly revenue ($703,538 in Q3 FY2026), up 59% year-over-year. This is the primary growth driver as installed base expands.
  2. Reader Hardware Sales: Initial reader hardware sales (DSR-Plus fluorescence reader) that create the installed base for recurring cartridge revenue. Reader sales surged 104% year-over-year in Q2 FY2026 to $246,519.
  3. Other Revenue: Other sales including supplementary products and services, representing 21% of Q3 revenue ($217,857), up 80% year-over-year, indicating broadening product ecosystem.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels8 records

Intelligent Bio Solutions product offering

Product offering

Core offering

Intelligent Bio Solutions develops and sells the Intelligent Fingerprinting Drug Screening System, which uses lateral flow assay cartridges and a portable DSR-Plus fluorescence reader to detect drug metabolites in fingerprint sweat. Sample collection takes seconds and results are produced in under ten minutes at the point of collection. The company also sells the SmarTest Patch, a wearable sweat patch for continuous drug detection over 7–10 days.

Product overview

Intelligent Bio Solutions offers a unified portfolio of non-invasive drug testing products based on fingerprint sweat analysis. The core offering is the Intelligent Fingerprinting Drug Screening System, comprising single-use Drug Screening Cartridges and the portable DSR-Plus Drug Screening Reader, which provides rapid point-of-collection screening for opiates, cocaine, methamphetamine, and cannabis with results in under 10 minutes. This is complemented by the SmarTest Patch, a wearable sweat patch enabling continuous 7-10 day drug monitoring for longer-term detection in justice and rehabilitation settings. The portfolio also includes a Confirmatory Drug Test Kit with LC-MS/MS laboratory analysis through accredited partner RASL for situations requiring definitive confirmation of non-negative screening results. Together, these products provide both immediate and continuous non-invasive sweat-based drug detection solutions.

Differentiator

Problem solved

Functional benefit

Brands

  • Intelligent Fingerprinting Drug Testing Solution: Non-invasive fingerprint sweat analysis drug testing system that screens for recent drug use including opiates, cocaine, methamphetamine, and cannabis with results in under ten minutes
  • SmarTest Patch

Products and services

  • Intelligent Fingerprinting Drug Screening System A rapid, non-invasive drug screening system that detects recent drug use (opiates, cocaine, methamphetamine, cannabis) by analysing fingerprint sweat. Combines single-use Drug Screening Cartridges with the portable DSR-Plus Reader; samples collected in seconds and results returned in under ten minutes. Designed for workplace screening by non-specialist staff.
  • Drug Screening Cartridges Single-use, tamper-proof lateral flow assay cartridges that collect fingerprint sweat and use fluorescence-labelled antibodies to selectively detect specific drugs or their metabolites. Self-locking sample seals support chain-of-custody integrity. Sold as recurring consumables for use with the DSR-Plus Reader.
  • DSR-Plus Drug Screening Reader A portable, highly sensitive fluorescence measurement instrument used to read Drug Screening Cartridges, producing negative or non-negative results for each drug within minutes. Designed for use by non-laboratory workplace personnel without specialised facilities.
  • SmarTest Patch A discreet, wearable sweat drug testing patch worn on the upper arm, chest, or back that enables continuous drug detection over a 7 to 10-day period. Tamper-evident and water-resistant; monitors substances including fentanyl, cocaine, opiates, benzodiazepine, buprenorphine, and methadone. Designed for longer-term monitoring in justice and rehabilitation settings.

Quantifiable outcome

  • 50% cost reduction vs urine-based testing
  • +5 more outcomes

Companies that use Intelligent Bio Solutions

Customer profile

Named customers7 records

Segments7 records

Ideal customer profiles4 records

Intelligent Bio Solutions technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Intelligent Bio Solutions partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Bouygues UKcoreChannel Partner/ Reseller/ Distributor · 24 February 2026Initial 13-site deployment with UK subsidiary of Bouygues Construction (global construction firm with 35,600 employees across 50+ countries). Transition from third-party testing services to in-house INBS fingerprint drug testing. Joint ROI analysis validated superior hygiene, operational efficiency, and cost savings. Viewed as collaborative partnership rather than traditional supplier agreement.
  • CenExel Clinical Research, Inc.coreImplementation/ SI/ Consulting Partner · 1 January 2026Nationwide clinical research site network partnership for FDA 510(k) clinical studies. Conducting Interference Study enrolling 75 participants, Method Comparison Study with 135 donor and 9 operator participants, and supporting Cut-off Study. Studies conducted under ICH GCP Guidelines to generate clinical evidence required for FDA submission.
  • Syrma Johari MedTech Ltd.coreTechnology or Integration · 31 December 2025Strategic manufacturing partnership to produce Intelligent Fingerprinting Drug Screening Reader. Expected to deliver over 40% reduction in annual production costs and approximately 20 percentage point improvement in gross margin. Syrma Johari's manufacturing capacity is approximately four times INBS's current capability with ISO 13485, MDSAP, FDA, and GMP certifications across 14 manufacturing locations in India, Europe, and the US. First readers successfully manufactured and shipped in February 2026.
  • Vlepis Pty Ltd.coreStrategic or Co-development Partner · 18 December 2025Non-exclusive strategic alliance to jointly develop and commercialize non-invasive testing and wearable health monitoring technologies. Leverages Vlepis's wearable patch and sensor technologies alongside INBS's fingerprint-based testing and SmarTest Patch products. Targets consumer health monitoring market valued at USD 42.7 billion in 2024, projected to reach USD 168.3 billion by 2030. Companies will combine R&D capabilities, distribution networks across 24+ countries, and regulatory expertise.
  • Racing Analytical Services Limited (RASL)coreImplementation/ SI/ Consulting PartnerNATA-accredited laboratory partner performing fingerprint confirmatory drug testing procedure. Provides gold standard LC-MS/MS analysis to confirm screening results and validate system accuracy for FDA 510(k) submission studies.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Intelligent Bio Solutions competitors and assessment

Company assessment

Direct peers

  • OraSure Technologies: OraSure develops rapid point-of-care diagnostics including oral-fluid drug testing products (Intercept). It is the most direct comparable to INBS in non-invasive rapid drug screening.
  • Psychemedics Corporation: Psychemedics pioneered hair-based workplace drug testing. It competes in the same employer drug-testing use cases as INBS via a different non-invasive sample matrix.
  • Drägerwerk: Dräger's Dräger DrugTest 5000 is a well-established oral-fluid point-of-collection workplace drug testing system, making it a direct head-to-head competitor in safety-critical industries where INBS also sells.
  • American Screening Corporation: American Screening distributes rapid drug test kits and point-of-care testing devices for workplace, clinical, and at-home use across multiple methodologies including urine, saliva, and surface tests.

Broad incumbents

  • Quest Diagnostics: Quest Diagnostics operates one of the largest clinical laboratory networks in the U.S. and is a major employer drug testing incumbent. INBS positions itself as a faster, point-of-collection alternative to lab-based urine testing.
  • Abbott Laboratories (Diagnostics): Abbott's diagnostics franchise spans rapid point-of-care and laboratory drug/toxicology testing. As a broad incumbent, Abbott is a likely competitor or potential partner for any FDA-cleared rapid drug screening platform.
  • Thermo Fisher Scientific: Thermo Fisher offers laboratory analytical instruments, reagents, and clinical diagnostics consumables overlapping with both INBS's DSR-Plus reader and lateral flow cartridge chemistry.
  • Bio-Rad Laboratories: Bio-Rad manufactures clinical diagnostics and life science research instruments, including quality controls and immunoassay reagents relevant to lateral flow and laboratory drug screening workflows.

Emerging players

  • Confirm BioSciences: Confirm BioSciences sells rapid urine- and saliva-based drug testing kits to workplace, clinical, and at-home users — an emerging player in the same customer segments INBS targets via fingerprint sweat.
  • Premier Biotech: Premier Biotech manufactures and distributes point-of-care drug screening devices and test cups for workplace and clinical use, overlapping with INBS's workplace drug-testing go-to-market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Intelligent Bio Solutions social profiles

Digital presence

Intelligent Bio Solutions compliance and trust

Trust signal

Compliance4 records

Intelligent Bio Solutions financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intelligent Bio Solutions leadership team

Management profile

Number of profiles

Profiles12 records

Intelligent Bio Solutions funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intelligent Bio Solutions M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intelligent Bio Solutions

What does Intelligent Bio Solutions do?

Intelligent Bio Solutions develops and sells the Intelligent Fingerprinting Drug Screening System, which uses lateral flow assay cartridges and a portable DSR-Plus fluorescence reader to detect drug metabolites in fingerprint sweat. Sample collection takes seconds and results are produced in under ten minutes at the point of collection. The company also sells the SmarTest Patch, a wearable sweat patch for continuous drug detection over 7–10 days.

Is Intelligent Bio Solutions a public or private company?

Intelligent Bio Solutions is a public company. It is classified as public and is currently operating.

When was Intelligent Bio Solutions founded?

Intelligent Bio Solutions was founded in 2017. It employs 51 to 100 people.

Where is Intelligent Bio Solutions based?

Intelligent Bio Solutions is headquartered in Botany, Australia, in the Oceania region.

How does Intelligent Bio Solutions make money?

Three revenue lines are on record. Cartridge Sales (Recurring Consumables) is the primary driver. The others are reader Hardware Sales and other Revenue.

Who are Intelligent Bio Solutions's main competitors?

Direct peers on record are OraSure Technologies, Psychemedics Corporation, Drägerwerk and American Screening Corporation. Broad incumbents are Quest Diagnostics, Abbott Laboratories (Diagnostics), Thermo Fisher Scientific and Bio-Rad Laboratories. Emerging players are Confirm BioSciences and Premier Biotech.

Does Intelligent Bio Solutions have an API?

No public API is recorded for Intelligent Bio Solutions.

What industry is Intelligent Bio Solutions in?

Intelligent Bio Solutions's product category is Drug Screening Diagnostics. Its primary akta.pro industry code is HLAHAOAG, Drug-of-Abuse & Toxicology Rapid Tests (Urine/saliva panels). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireIntelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year GrowthIntelligent Bio Solutions reported record fiscal Q1 2027 revenue of $1.39 million, up 25% year-over-year, with cartridge sales accounting for 61% of revenue. The company submitted its FDA 510(k) premarket notification for its drug screening system, a key step toward U.S. market entry.Stock TitanIntelligent Bio Solutions Q1 revenue up 25% YoY to $1.39MIntelligent Bio Solutions reported fiscal Q1 2027 revenue of $1.39 million, up 25% year-over-year, with cartridge consumables accounting for 61% of sales. The company submitted its FDA 510(k) premarket notification for its drug screening system, a key step toward planned U.S. market entry.GlobeNewswireIntelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12Intelligent Bio Solutions will present at the Webull Biotech Webinar on November 12, 2026, with VP of Global Sales Doug Heath. The company's sweat-based drug testing solutions screen for common drugs of abuse, with results in under ten minutes. The presentation will be virtual with a live Q&A.Stock TitanIntelligent Bio Solutions Sets Webull Webinar for Nov. 12Intelligent Bio Solutions will present at the Webull Biotech Webinar on November 12, 2026, with VP of Global Sales Doug Heath as speaker. The virtual session includes a live Q&A, and registration is available via a provided link.Ticker ReportIntelligent Bio Solutions Inc. (NASDAQ:INBS) Shares Shorted: Short Interest Down 51.2% in SeptemberIntelligent Bio Solutions' short interest fell 51.2% to 58,294 shares as of September 30th, with 1.8% of shares sold short. The stock traded down 2% to $1.45, and analysts have a consensus "Reduce" rating.Markets DailyComparing QT Imaging (NASDAQ:QTI) & Intelligent Bio Solutions (NASDAQ:INBS)QT Imaging and Intelligent Bio Solutions are compared on profitability, valuation, and analyst ratings. QT Imaging has a lower beta, higher revenue, and a better analyst consensus with a $8.00 target price, suggesting a 226.53% upside. The comparison concludes QT Imaging is more favorable.American Banking and Market NewsHead to Head Analysis: Intelligent Bio Solutions (NASDAQ:INBS) versus QT Imaging (NASDAQ:QTI)QT Imaging beats Intelligent Bio Solutions on 9 of 14 factors, including lower volatility, higher institutional ownership, and a stronger analyst consensus. QT Imaging trades at a lower price-to-earnings ratio and has a consensus price target of $8.00, implying 198.51% upside.Ticker ReportIntelligent Bio Solutions Inc. (NASDAQ:INBS) Short Interest UpdateShort interest in Intelligent Bio Solutions surged 255% to 119,549 shares as of September 15th, representing 3.7% of shares. Analysts have assigned a "Reduce" average rating, with one "sell" and one "hold" rating. The stock opened at $1.70, below its 50-day moving average of $2.14.Seeking AlphaIntelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System TranscriptIntelligent Bio Solutions submitted its 510(k) premarket notification to the FDA for its intelligent fingerprinting drug screening system, seeking clearance to enter the U.S. market. The company hosted a fireside chat to discuss progress, data submitted, and next steps.American Banking and Market NewsReviewing Verano (OTCMKTS:VRNOF) and Intelligent Bio Solutions (NASDAQ:INBS)Verano and Intelligent Bio Solutions are compared on dividends, risk, earnings, profitability, institutional ownership, valuation, and analyst recommendations. Verano beats on 8 of 13 factors, including lower volatility and a lower price-to-earnings ratio, while Intelligent Bio Solutions has higher institutional ownership but far higher volatility.